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ed significantly with urinary hepcidin-25 concentrations, 
whereas serum and urinary prohepcidin were not associated 
with one another or with the homologous or converse for-
mats for hepcidin-25. Serum ferritin and transferrin satura-
tion were significantly correlated with serum hepcidin-25 
concentrations, but not with urine hepcidin-25 or with either 
format of prohepcidin.  Conclusion: Hepcidin-25 shows cor-
respondence across biological fluids, and the background 
‘status’ of hepcidin activation may be related to the host’s 
iron stores, whereas prohepcidin concentrations showed no 
promise in this regard.  Copyright © 2011 S. Karger AG, Basel
 Introduction
 Throughout the history of clinical chemistry, when 
analysts develop an assay to detect and quantify a vari-
able of biological relevance, the investigation of its con-
centration in human biological fluids and tissues follows 
shortly thereafter. Hepcidin was first described in 2001 
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 Abstract
 Background/Aims: Prohepcidin and the active form hepci-
din-25 are two variants of the peptide hormone hepcidin for 
iron homoeostasis. Their regulatory role and usefulness as 
biomarkers of the iron status are uncertain. Our aim is to de-
scribe the intra-individual variance of serum and urinary 
hepcidin-25 and prohepcidin concentrations, the mutual as-
sociations of the 4 hepcidin formats, and their correspon-
dence with iron status variables in male Guatemalan volun-
teers.  Methods: Eight healthy adult males provided serial 
samples of serum and urine without previous iron dosing 
over 6 intervals during a 9-week protocol period. Prohepci-
din was assayed by a commercial enzyme immunoassay,
and hepcidin-25 species in serum and urine were analysed 
by time-of-flight mass spectrometry after prior enrichment 
procedures.  Results: Serum hepcidin-25 levels correlat - 
 Received: April 1, 2010
 Accepted after revision: April 11, 2011
 Published online: June 8, 2011 
 Klaus Schuemann
 Research Centre for Nutrition and Food Science
 Technische Universität München
 DE–85350 Freising (Germany)
 Tel. +49 816 171 3400, E-Mail k.schuemann@lrz.uni.münchen.de 
 © 2011 S. Karger AG, Basel
 0250–6807/11/0582–0158$38.00/0 
 Accessible online at:
 www.karger.com/anm 
 Prohepcidin and Hepcidin-25 Correlates 
as Biomarkers in Healthy Men 
Ann Nutr Metab 2011;58:158–166 159
 [1–3] . Since then, literature on hepcidin expanded expo-
nentially, and the references given here and below are not 
meant to be exhaustive. Hepcidin is a peptide hormone 
that exists in various chemical forms. It has a precursor 
entity (prohepcidin) of an 84-amino acid chain length 
synthesized primarily in the liver. Prohepcidin analysis 
in human samples was described by Kulaksiz et al.  [4] and 
was systematically applied in urine  [5, 6] and serum/plas-
ma  [5–9] . Some workers found physiologically expected 
responses  [6, 8, 10] , whereas others did not  [5, 7, 11, 12] , 
leaving questions regarding the true identity and meta-
bolic and regulatory role of prohepcidin unanswered. 
The active form of hepcidin has 25 amino acid residues 
(hepcidin-25); it can be analysed both in the circulation 
 [13–25] and the urine  [13, 26–39] , either as hepcidin-25 
 [4, 13, 16, 23, 24] or along with other isoforms (hepci-
din-20 and hepcidin-22)  [18, 20–22] . An assay adapted to 
determine hepcidin-25 has been specifically developed in 
one of our laboratories (D.W.S.)  [14] and was used in this 
study.
 The present report is part of a central study that com-
pares changes in serum iron and non-transferrin-bound 
iron after weekly ingestion of oral iron preparations at 6 
increasing single dose levels (0, 15, 30, 60, 120 and 240 mg 
Fe) given over a period of 9 weeks at weekly intervals (14 
days after the 2 highest dosages). This data analysis re-
stricts itself to basal samples collected without iron inges-
tion and permits repeated intra-individual comparison of 
all 4 hepcidin formats – prohepcidin and hepcidin-25, 
each in serum and urine – in healthy human subjects in 
a developing country environment. It includes the me-
ticulous characterization of individual iron status (hae-
moglobin, ferritin, transferrin saturation) and the state of 
inflammatory reactivity (white blood count and cyto-
kines) in the context of the central study, with the goal to 
check in principle if any of the urinary hepcidin species 
may serve as a non-invasive variable to assess body iron 
status in developing countries.
 Subjects and Methods
 Subjects
 A group of 8 healthy Guatemalan males, aged between 19 and 
54 years, were enrolled in the study. None of them reported any 
history of chronic or acute diseases, or consumption of nutrition-
al supplements during the previous 6 months. The Human Sub-
jects Committee of the Center for Studies of Sensory Impairment, 
Aging and Metabolism approved the protocol. Subjects signed 
written informed consent and were compensated for their par-
ticipation.
 Study Design
 This paper uses and reports only the values obtained in the 
first morning (fasting) specimen of serum or urine. The fasting 
data set supplies up to 7 values per subject or up to 56 values per 
group analysis, except where missing fasting values might have 
occurred. Occasionally, additional samples were drafted for con-
firmation as described in the text.
 Sample Collection Procedures
 Five millilitres of venous blood were sampled in the morning 
in a fasting state prior to administration of ferrous sulphate syrup 
(Fer-In-Sol  , Mead Johnson, Evansville, Ind., USA). In the pla-
cebo group, all 4 samples were included in the analysis, i.e. 1 sam-
ple obtained before and 3 samples collected after intake of plain 
water. Serum was obtained after clotting and centrifugation at 
3,000 rpm for 5 min, then frozen in aliquots at –20   °   C. First morn-
ing urines were collected at home, brought to the laboratory on 
ice, aliquoted and stored on dry ice after addition of phenylmeth-
ansulfonylfluorid (1   l PMSF/ml urine; Sigma, Munich, Germa-
ny). No alcoholic beverages were permitted during the 24 h before 
each study day, and smoking was not allowed on blood extraction 
days.
 Laboratory Assays
 Iron Status Parameters. Haemoglobin concentration, leuco-
cytes and packed cell volume were determined in Guatemala City 
at baseline and at the end of the study in an automated haemato-
logical profile analyser (Cell-Ruby, Ruby TM , Abbott Diagnostics, 
Santa Clara, Calif., USA). Serum ferritin and transferrin were de-
termined from frozen samples by turbimetric tests (Roche, 
Mannheim, Germany), and serum iron concentration was mea-
sured by a ferrozine-based assay (Roche). Transferrin saturation 
was calculated from serum transferrin and serum iron concentra-
tions.
 Inflammatory and Oxidative Markers in Serum and Urine. In-
terleukin-4 and tumour necrosis factor-  concentrations, reflect-
ing serum levels of critical anti-inflammatory and pro-inflamma-
tory cytokines, were quantified in the serum by use of the Quan-
tikine  Immunoassays (R&D Systems, Wiesbaden, Germany). 
 Determination of Hepcidin Forms. Prohepcidin concentra-
tions in serum and urine were determined by an enzyme immu-
noassay kit (DRG Instruments GmbH, Germany). Urinary hepci-
din-25 was semi-quantified as described earlier  [13] . Serum hep-
cidin-25 was measured by use of matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
performed by an updated form of our previously described meth-
od  [13, 14] . For the quantification of hepcidin in serum, an inter-
nal standard (synthetic hepcidin-24, Peptide International Inc., 
Louisville, Ky., USA) was added to 100   l urine and 50   l serum 
before total hepcidin was isolated from the sample with Macro-
Prep  CM Support beads (Bio-Rad Laboratories, Hercules, Calif., 
USA) as described by Park et al.  [2] . Next, hepcidin was applied to 
an MSP 96 polished-steel MALDI target plate followed by the ad-
dition of energy absorbing matrix, 5 mg   -cyano-4-hydroxy-cin-
namic acid in 1 ml 50% acetonitril and 0.1% trifluoroacetic acid, 
all in nitrogen atmosphere. Mass-to-charge (m/z) spectra were 
generated using MALDI-TOF MS (Microflex LT, Bruker Dalton-
ics GmbH, Bremen, Germany) in positive, linear ion mode and 
500 laser shots (initial laser power 60%, laser attenuator offset 25% 
and range 20%). Pulsed ion extraction was set to 150 ns.
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 Urine hepcidin-25 was normalized to creatinine concentra-
tions in the same specimen, and relative concentrations were ex-
pressed as mega-intensity units per mmol creatinine [(Mint)/
mmol]. Concentrations of serum hepcidin-25 were expressed as 
n M . For urine hepcidin-25 analysis, chip-to-chip variation was 
22% at the high intensity of 48 Mint to 27.5% at the lower inten-
sity of 20 Mint. For serum hepcidin-25, the intra-run coefficient 
of variation (CV) was 3.7% at 7.9 n M , 2.3% at 13.4 n M and 2.2% at 
3.1 n M . The inter-run CV was 9.1% at 7.8 n M and 3.9% at 12.9 n M 
(all samples, n = 8).
 Assessment of the reliability of hepcidin-25 determination af-
ter storage for 24 months at –20   °   C was based on the disappear-
ance of a number of peaks in the serum mass spectrometry profile 
around 8,000 m/z, as observed in sera that remain at 4   °   C for a 
prolonged period of time ( 1 4 days). The disappearance is likely 
due to disintegration of some proteins. These samples were scored 
as questionable and were not included in the line of ‘selected sam-
ples’ in table 2. The impact of the extended storage period on hep-
cidin peaks around 2,800 m/z was not checked.
 Data Handling, Presentation and Statistical Analyses
 Results on hepcidin forms from the different collaborating 
laboratories were initially given in different units. Thus, urinary 
prohepcidin values were reported in ng/l and ng/mg of creatinine, 
respectively. For harmonization of units within the present re-
port, molar values were converted into gravimetric units by mul-
tiplying them by the factor of 2.789 (MW of hepcidin-25 in kDa) 
for the serum hepcidin-25 and relating time to creatinine. 
 Descriptive statistics included the mean, standard deviation 
and median for all of the variables measured across time in the 
study. Here, the arithmetic mean was used universally, even for 
ferritin and cytokines, which are generally expressed as geomet-
ric means because of the typical skewed distribution. This was 
done because of the small sample size and an unfamiliarity of 
typical distributions of these candidate biomarkers. We used 
analysis of variance (ANOVA) to compare the averaged hepcidin 
formats across the 8 participants. As the variables were not al-
ways normally distributed, both the Pearson product moment 
least square and the Spearman rank order correlation coeffi-
cients were generated to explore associations between variables 
in a binary manner.
 Results
 Demographic, Haematological and Inflammatory 
Characteristics of the Subjects
 The demographic, haematological and inflammatory 
status characteristics of the 8 healthy male volunteers 
(subjects A–H) are presented in  table 1 . The average age 
of the subjects was 34  8 10 years, and the body mass in-
dex varied from 19.4 to 27.4. Only subject G was in the 
overweight range, and none was in the underweight do-
main.
 All haemoglobin values were normal, even as adjusted 
for the altitude of 1,484 m above sea level of Guatemala 
City  [40] . The individual mean serum ferritin values were 
all above the iron deficiency threshold, being over 4 times 
higher than the cut-off point for iron deficiency of 12 
  g/l. Similarly, transferrin saturation was in the normal 
range (16–45%)  [41] .
 Three indicators relate to ongoing systemic inflam-
mation. The white blood count was marginally elevated 
above 10,000 cm 3  in 1 subject, but remained in the nor-
mal range in all other subjects. All mean values for tu-
mour necrosis factor-  were within the normative range 
( ! 20 pg/ml). Undetectable levels of interleukin-4 were 
found in most samples, with the median being undetect-
able (zero) in all subjects (normative range  ! 13 pg/ml). 
With regards to hepcidin being an acute-phase reactant 
protein  [42, 43] , these values assure that inflammation 
was not evident in these subjects throughout the course 
of sampling.
 Descriptive Statistics for Hepcidin Forms in the Study 
Sample
 Table 2 provides the individual and sample descriptive 
statistics for the 4 formats of hepcidin, i.e. prohepcidin 
 Table 1.  Demographic characteristics, nutritional and haematological status and inflammatory markers in 8 adult volunteers (subjects A–H)
Variables A B C D E F G H Mean SD Median
Age 1 , years 25 42 19 35 33 54 33 28 34 10 33
BMI 1 19.4 19.6 20.0 20.0 21.9 24.7 27.4 22.0 21.9 2.7 21.0
Haemoglobin 1 , g/dl 14.9 14.3 17.6 15.6 15.8 15.3 15.8 15.8 15.6 0.9 15.7
Ferritin 2 ,   g/l 56 (19) 276 (36) 122 (32) 59 (13) 70 (27) 228 (69) 156 (35) 129 (38) 143 89 115
TfSat 2 , % 23 (14) 32 (10) 38 (19) 20 (5) 23 (7) 41 (25) 29 (6) 30 (7) 30 14 25
WBC 1 , cells/mm 3 6.8 4.3 10.2 6.2 5.3 7.7 6.8 5.9 6.65 1.8 6.5
TNF-  2 , pg/ml 1.41 (2.47) 2.26 (12.74) 1.07 (0.65) 2.62 (3.84) 2.53 (7.08) 2.74 (11.52) 2.86 (20.05) 2.82 (26.53) 2.38 1.43 2.11
IL-4 2 , pg/ml 0 (0) 0.005 (0) 0.005 (0) 0.0003 (0) 0 (0) 0.02 (0) 0 (0) 0 (0) 0.001 0.002 0.0000
S D = Standard deviation; BMI = body mass index; WBC = white blood cell count; TNF-  = tumour necrosis factor-  ; IL-4 = interleukin-4. Values 
in parentheses represent the standard deviation of the arithmetic mean.
 1  Values at baseline evaluation, 1 per subject.  2  Values for fasting values on up to 7 occasions. 
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and hepcidin-25 each in serum and urine. All data in the 
urine have been normalized by creatinine to correct for 
variability in hydration state and urine concentration. 
The individual subjects’ means of prohepcidin in early 
morning fasting urine samples on the 6 occasions ranged 
from 83.9 (subject C) to 157.6 ng/mg creatinine (subject E). 
There was a 1.9-fold difference between the lowest and 
highest level. The intra-individual CV, i.e. the standard 
deviation expressed as a percentage of the mean, for fast-
ing samples ranged from 29 to 67%. The pooled average of 
all samples analysed across all subjects was 122.9  8 55.6 
ng prohepcidin/mg creatinine; the CV was 45%.  Table 2 
also shows the tabulations for creatinine-normalized uri-
nary hepcidin-25. It shows a range of 3.1–21.3 mega-inten-
sity units/mg creatinine  ! 10 –3 , i.e. a 6.8-fold difference 
among the means of the subjects. The CVs were in the 
40–100% range. The pooled average was 10.3  8 9.9 mega-
intensity units/mg creatinine  ! 10 –3 ; the CV was  1 90%.
 In the serum, prohepcidin concentrations showed a 1.4-
fold difference between the low and high individual means 
of 160 and 222 ng/ml. The CVs ranged from 20 to 38%. The 
overall mean was 189  8 60 ng/ml, with a CV of 32% ( ta-
ble 2 ). Due to long storage, concentrations of hepcidin-25 
in serum were analysed in two tiers: (1) all samples irre-
spective of quality criteria, and (2) the selected samples 
which conformed to the pre-established quality criterion 
of not showing disappearance of a number of peaks in the 
serum mass spectrum around 8,000 m/z ( table 2 ). For the 
selected set of serum hepcidin-25 concentrations, there 
was a 5-fold difference across the individual’s pooled, se-
rial values, ranging from 1.31  8 0.56 ng/ml (CV 43%) to 
6.83  8 4.85 ng/ml (CV 71%). The overall mean was 4.43 
 8 2.62 ng/ml, with a CV of 59%. No subject-to-subject 
differences of statistical significance at the 5% level were 
determined by ANOVA for any of the lines in  table 2 .
 Associations within and between Prohepcidin and 
Hepcidin-25 Forms in Serum and Urine 
 The approach to evaluating associations among the 
different hepcidin forms in the same specimen or in the 
corresponding, alternative biological fluid sample was to 
conduct both the Pearson product moment least square 
and Spearman rank order correlation regressions ( ta-
ble 3 ). Different hepcidin formats, e.g., hepcidin-25 and 
prohepcidin in the same medium, or hepcidin-25 in se-
rum versus urine and prohepcidin in serum versus urine, 
showed no significant associations in most cases. An ex-
ception was the high correlation between urinary hepci-
din-25 with urinary prohepcidin, in which the Pearson 
correlation coefficient reached statistical significance
(r = 0.432; p = 0.001;  table 3 ). However, there was no sig-
nificant association between urinary prohepcidin and its 
homologue in the circulation at concurrent times (p = 
0.833;  table 3 ). By contrast, statistically significant r val-
ues, ranging in magnitude from 0.398 to 0.534 ( table 3 ), 
were seen for the associations between urinary and se-
rum hepcidin-25 values.
 Association between Underlying Serum Biomarkers 
of Individual Iron Status (Serum Ferritin, Percent 
Transferrin Saturation) and Hepcidin Forms Assayed 
in Serum and Urine 
 The next question relates to any potential influence of 
background iron status on the background set points for 
 Table 2.  Normative values for urinary and serum hepcidin forms for 8 adult volunteers (subjects A–H) collected in the fasting state
Variables A B C D E F G H Mean SD Median
Urine prohepcidin,
ng/mg creatinine 99.4 (42.5) 131.2 (67.2) 83.9 (31.9) 119.9 (38.5) 157.6 (53.4) 150.5 (100.7) 139.8 (44.6) 115.5 (33.2) 122.9 55.6 115.0
Urine hepcidin-25 T0 1 , mega-
intensity units/mg creatinine 
 ! 10 –3 
8.5 (7.7) 21.3 (13.5) 13.8 (12.4) 3.1 (3.1) 7.0 (4.8) 18.9 (12.0) 4.2 (3.8) 9.4 (3.8) 10.3 9.9 7.4
Serum prohepcidin T0 2 , ng/ml 206 (66) 222 (48) 213 (64) 160 (51) 220 (45) 202 (62) 175 (66) 162 (53) 189 60 180
Serum hepcidin-25 T0 2, 3 , ng/ml 2.34 (0.80) 4.91 (1.98) 5.13 (4.10) 1.59 (0.50) 5.02 (4.08) 4.85 (1.90) 4.13 (1.37) 3.76 (2.15) 3.76 2.48 3.54
Serum selected hepcidin-25 T0 4 ,
ng/ml 5.19 (0.84) 6.44 (1.28) 6.83 (4.85) 1.31 (0.56) 4.57 (1.62) 5.44 (1.14) 4.74 (0.81) 4.46 (1.48) 4.43 2.62 4.41
S D = Standard deviation. Values in parentheses represent the standard deviation of the arithmetic mean.
 1  All values reported represent up to 19 occasions per subject.  2  Values for fasting values on up to 7 occasions per subject.  3  Based on all analyses performed. 
 4  Based on analyses selected for congruence of concentration value.
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hepcidin in circulation and in urine ( table 4 ). For serum 
hepcidin-25, significant correlations were seen wheth - 
er using the selected samples or all measurements. Ap-
proaching statistical significance, with a Pearson r value 
of 0.661 (p = 0.075), was the association of fasting urinary 
hepcidin-25 with the pooled ferritin value for an indi-
vidual ( table  4 ). Serum hepcidin-25 correlated signifi-
cantly with serum ferritin ( table 4 ). 
 The degree of saturation of serum transferrin has long 
been used as a clinical marker of iron availability even 
before ferritin assays became available in the 1970s  [41] . 
While ferritin has intrinsically high within-individual 
stability, the diurnal fluctuations in serum iron are well 
known. Therefore, only the fasting percent transferrin 
saturation (%TfSat) status is given here, reflecting the 
iron status of the subjects. Thus, this variable was sub-
jected to correlation coefficient analysis ( table  4 ). The 
pattern of significant and near-significant associations 
for fasting %TfSat with hepcidin forms virtually mim-
icked those with ferritin ( table 4 ).
 Discussion
 Over the past years, interest has emerged around hep-
cidin, a hormone of hepatic origin, which is of central 
importance for the control of iron absorption and main-
tenance of body iron homeostasis  [9, 43, 44] . The capac-
 Table 3.  Pearson and Spearman correlation coefficients for the binary associations of all combinations of hep-
cidin forms in the fasting state
 Binary correlations Zero time values 
Pearson  Spearman 
r  p  r  p 
 Urinary prohepcidin vs. urinary hepcidin-25 0.432  0.001  0.136  0.332 
 Serum hepcidin-25 (all) vs. serum prohepcidin 0.214  0.148  0.253  0.086 
 Serum hepcidin-25 (selected) vs. serum prohepcidin 0.081  0.678  0.186  0.333 
 Serum prohepcidin vs. urinary hepcidin-25 0.193  0.179  0.200  0.163 
 Serum hepcidin-25 (all) vs. urinary hepcidin-25 0.456  0.001  0.398  0.004 
 Serum hepcidin-25 (selected) vs. urinary hepcidin-25 0.534  0.002  0.430  0.016 
 Serum hepcidin-25 (all) vs. urinary prohepcidin 0.036  0.806  0.051  0.727 
 Serum hepcidin-25 (selected) vs. urinary prohepcidin  –0.075  0.687  0.108  0.563 
 Serum prohepcidin vs. urinary prohepcidin  –0.031  0.833  0.010  0.944 
 Ita licized figures mark significant correlations (p < 0.05). 
 Table 4. P earson and Spearman correlation coefficients for two markers of iron status (mean of all ferritin measurements, mean of 
fasting %TfSat) with all-study means for the various serum and urinary hepcidin forms (n = 8 per correlation)
 Hepcidin variables Ferritin (all times, pooled) %TfSat (zero times) 
Pearson Spearman Pearson Spearman 
r  p r  p r  p r  p 
 Urinary prohepcidin  –0.157  0.710  –0.500  0.207  –0.078  0.854  –0.108  0.799 
 Urinary hepcidin-25 0.661  0.075 0.405  0.320 0.626  0.097 0.503  0.204 
 Serum prohepcidin 0.468  0.243 0.405  0.320  –0.412  0.311  –0.333  0.420 
 Serum hepcidin-25 (all) 0.921  0.009 0.810  0.015 0.831  0.011 0.690  0.058 
 Serum hepcidin-25 (selected) 0.921  0.009 0.829  0.042 0.710  0.049 0.524  0.183 
 Ita licized figures mark significant correlations (p < 0.05). 
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ity for assaying the chemical forms of hepcidin in various 
biological fluids is still in its infancy, though meanwhile, 
serum hepcidin-25 values in control populations are 
available for reference  [14, 20] , and assays worldwide were 
compared in a first round robin  [45] . While reports on 
detection and quantification of prohepcidin, hepcidin-25, 
or both, in human urine proliferated [e.g., see ref.  7, 26–
39 ], assays related to circulating hepcidin-25 were less 
common before corresponding serum assays had been 
developed  [13, 15–24] .
 Strengths and Limitations of the Available Hepcidin 
Data Set
 The major strength of the present study is the simul-
taneous measurement of all 4 formats of hepcidin con-
currently in the same individual; this allows for all pos-
sible combinations of simultaneous inter-comparison. 
Two obvious limitations of this study relate to sample 
size and specimen stability. The present trial was pri-
marily designed as a metabolic study, and the 8 individ-
uals may not be representative of the general population 
for men, not even for healthy males in Guatemala. More-
over, given the well-established differences in iron status 
between men and women  [46] , hepcidin status may dif-
fer between the sexes; the absence of any female partici-
pants leaves extrapolation across sex in abeyance. At the 
time of designing and executing the present study in 
2005, an assay for serum hepcidin-25 did not exist with-
in our collaboration network; it only became available as 
of 2007  [13] . Thus, serum aliquots used for the hepci-
din-25 assay underwent 2 years of storage at –20    °    C, 
whereas assays of the urine for both prohepcidin and 
hepcidin-25 and of serum for prohepcidin were per-
formed in 2005. On the one hand, this leads to a dilemma 
of inter-variable consistency and data interpretation. On 
the other hand, observation of only small differences be-
tween hepcidin-25 values analysed in all collected sam-
ples as compared to those that certified by internal qual-
ity standards as well as the extent of agreement between 
these two sets ( table 2 ) suggest a comparably high stabil-
ity of serum hepcidin-25. The presented data obtained in 
fasting morning samples of serum and urine and their 
correlation among each other should begin to contribute 
to a familiarity with what normative concentrations in 
healthy adult men in an urban setting in a tropical nation 
might be. The caveat for the utility of the present data as 
reference values, of course, is the limited number of sub-
jects. 
 Comparison and Inter-Correlations of the 4 Hepcidin 
Forms
 The primary purpose of this publication was a focus 
on the association among the 4 different forms of hepci-
din that can now be quantified in clinical chemistry. In 
agreement with the conclusion by Roe et al.  [11] and Kem-
na et al.  [47] , which discarded any biological utility from 
assaying serum prohepcidin, we confirm a lack of asso-
ciation of this format with other hepcidin forms. 
 In the context of mutual regulation of iron status and 
hepcidin-25 synthesis, the 1–2 orders of magnitude (i.e. 
10–100 fold) greater concentration of prohepcidin com-
pared to hepcidin-25 in serum ( table 2 ) is consistent with 
how a precursor and an active derivative might be related 
to one another. The significant association between se-
rum and urinary hepcidin-25 concentrations is in agree-
ment with this format being filtered by the glomerulus 
and being 95–100% reabsorbed by the proximal tubulus 
 [14, 20] . In contrast, the lacking correlation between pro-
hepcidin and both serum and urine hepcidin-25 raises 
questions about the true identity and possible regulatory 
role of prohepcidin.
 Relationship between the 4 Hepcidin Formats and the 
Subjects’ Iron Status 
 Serum hepcidin and serum prohepcidin did not cor-
relate in earlier trials  [47] , while hepcidin-25 in urine and 
serum did  [14, 20] . Because of the totally non-invasive 
collection format for urine specimens, urinary biomark-
ers, when reliable and useful, are ideal for population sur-
veys. Blood drawing is inconvenient due to cultural fac-
tors and carries the risk to transmit blood-borne diseases. 
In particular for iron status assessment in the context of 
targeted iron supplementation to iron-deficient children 
in malaria-endemic areas, it would be useful to have a 
 reliable urinary marker  [48] . Tempting as it would be to 
anticipate a non-invasive biomarker for iron status in the 
measurement of urinary hepcidin-25, the observed with-
in-subject instability militates against its ever serving 
alone as a reliable screening value for individual iron sta-
tus  [49] . However, for the assessment of large groups, av-
eraged values of urinary concentrations of the active hor-
mone could yield discriminations among iron-replete 
and iron-depleted populations, which would be of major 
importance in field studies ( table  4 ) and needs further 
investigation.
 With the aforementioned caveats on storage time and 
the limited number of volunteers in mind, issues of var-
iance and stability within assays can be informative. 
When fasting hepcidin values for all 4 formats were aver-
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aged within individuals, coefficients of variations were 
relatively large over the observation period of 9 weeks ( ta-
ble  2 ). Inter-individual ANOVA comparisons failed to 
find any significant differences between the 8 individuals 
for any of the hepcidin formats under these conditions. 
However, fasting hepcidin-25 of both iron statuses, either 
low or high, showed an appropriate reciprocal association 
of hepcidin-25 with classical markers of iron status in 
earlier trials  [14, 20, 50] . Accordingly, a concept of hepci-
din individuality would seem to be supported by the ar-
ray of positive associations found between the baseline 
hepcidin-25 concentrations in serum (and the trends in 
urine) and the two indicators of human iron status – fer-
ritin and %TfSat ( table 4 ) – which is in accordance with 
findings by Kroot et al.  [49] . Thus, serum values of hep-
cidin-25 may have a potential as iron status indicator. 
However, this is more promising on the collective group 
basis, as the large intra-individual standard deviations 
observed over time seem to call for repeated hepcidin-25 
determinations in individuals to develop a stable esti-
mate. Serum and urinary prohepcidin, by contrast, cor-
related much less well with iron status, showing no prom-
ise as iron status indicators in our data set ( table 4 ).
 Comparison of Our Findings with Those of Other 
Investigations 
 Recently, Ganz and collaborators  [20] have explored 
some of the same associations between serum and uri-
nary hepcidin-25. In this regard, they reported a correla-
tion coefficient of 0.82 for serum versus urine, also with 
adjustment for creatinine, whereas we found an r value of 
0.46 with an analogous Pearson regression. Our correla-
tion coefficient of r = 0.92 compares favourably with and 
confirms the r = 0.63 association observed in the Pearson 
regression of circulating ferritin with serum hepcidin-25 
in the recent report by Ganz et al.  [20] and with r = 0.68 
reported by Swinkels et al.  [14] .
 Conclusions
 The findings from repeated measurements of the pu-
tative precursor and the hormonally active forms of hep-
cidin in a limited number of healthy males provide some 
initial descriptive data and indications of interactions 
among the different forms. As a circulating hormone, 
both hepcidin moieties emulate the nature of other 
known hormones. Moreover, the significant association 
between hepcidin-25 in serum, and the weak correlation 
of hepcidin-25 in urine with the iron status indicators 
determined in parallel, suggest a certain promise of these 
variables as iron status markers. By contrast, no similar 
association was found for prohepcidin formats. Now that 
assays for two forms of the hepcidin hormone have de-
buted for multiple biological fluids in clinical chemistry, 
the way is cleared to further address the biological and 
interactive questions set forth in this analysis. 
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